Latest Neuroblastoma Stories
Administering a new form of immunotherapy to children with neuroblastoma, a nervous system cancer, increased the percentage of those who were alive and free of disease progression after two years.
A particularly aggressive childhood cancer can be fought successfully with far less chemotherapy than previously believed, avoiding harmful side effects caused by cancer drugs.
Using immunotherapyâ€”biologic agents that stimulate the bodyâ€™s immune systemâ€”pediatric oncologists have achieved the first substantial increase in over a decade in cure rates for the childhood cancer neuroblastoma.
-- New Standard of Care in High-Risk Neuroblastoma Seen in Immunotherapy Results-- PHILADELPHIA, Sept.
All amounts are in U.S. dollars QUEBEC CITY, Aug. 12 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc.
QUEBEC CITY, July 14 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrine therapy, today announced that its partner, Keryx Biopharmaceuticals, Inc.
NEW YORK, July 14 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that KRX-0401 (perifosine) has received Orphan Drug designation from the U.S.
CHOP oncology chief working to translate his lab's genetic findings into treatments.
--CHOP Oncology Chief Working to Translate His Lab's Genetic Findings into Treatments-- PHILADELPHIA, June 14 /PRNewswire-USNewswire/ -- Pediatric oncologist John M. Maris, M.D., describes the current state of the science in combating neuroblastoma, the most common solid cancer of early childhood.
--In Colket Building, Scientists Will Translate Research into Real-Life Treatments for Children -- PHILADELPHIA, June 9 /PRNewswire-USNewswire/ -- The Children's Hospital of Philadelphia will dedicate its new Ruth and Tristram Colket, Jr.
- A trick or prank.